World Official: EU agency to confirm AstraZeneca blood clot link
Canada pauses AstraZeneca vaccine for under 55
TORONTO (AP) — Canada on Monday suspended the use of the Oxford-AstraZeneca coronavirus vaccine for people under age 55 following concerns it might be linked to rare blood clots. The National Advisory Committee on Immunization had recommended the pause for safety reasons and the Canadian provinces, which administer health in the country, announced the suspension Monday. “There is substantial uncertainty about the benefit of providing AstraZeneca Covid-19 vaccines to adults under 55 given the potential risks,” said Dr. Shelley Deeks, vice chair of the National Advisory Committee on Immunization.
ROME (AP) — A top official at the European Medicines Agency says there is a causal link between AstraZeneca's coronavirus vaccine and rare blood clots, but that it's unclear what the connection is and the benefits of taking the vaccine still outweigh the risks of getting COVID-19.
Marco Cavaleri, head of health threats and vaccine strategy at the Amsterdam-based agency, told Rome's Il Messaggero newspaper on Tuesday that the EU medicines regulator is preparing to make a more definitive statement on the topic this week.
UK finds 30 blood clot cases after AstraZeneca jab
The cases identified by the medicines regulator were out of more than 18 million doses given.The Medicines and Healthcare products Regulatory Agency (MHRA) says the risk of having this type of clot is "very small".
Based on the evidence to date, Cavaleri said there's a clear association between the AstraZeneca vaccine and the dozens of rare blood clots that have been reported worldwide amid the tens of millions of vaccine jabs that have been given out.
“It is becoming more and more difficult to affirm that there isn’t a cause-and-effect relationship between AstraZeneca vaccines and the very rare cases of blood clots associated with a low level of platelets,” Cavaleri was quoted as saying.
Asked about Cavaleri’s comments, the EMA press office said its evaluation “has not yet reached a conclusion and the review is currently ongoing.” It said it planned a press conference as soon as the review is finalized, possibly Wednesday or Thursday.
U.K. Says AstraZeneca Shot Safe Even After 7 Blood Clot Deaths
(Bloomberg) -- The U.K. confirmed seven people had died from rare blood clots after receiving AstraZeneca Plc’s Covid-19 vaccine and Australia is also investigating a case of clotting, raising questions about the safety of the widely used coronavirus shot. The U.K.’s Medicines and Healthcare Products Regulatory Agency said Saturday that of 30 cases of clotting and low blood platelets identified in people in the U.K. who had received the shot through March 24, seven had died. More than 18 million doses have been administered in the country and the regulator insists the shot is safe.
AstraZeneca did not immediately respond to a request for comment.
Last month, more than a dozen countries, including Germany, suspended their use of AstraZeneca over the blood clot issue. Most EU nations restarted on March 19 — some with age restrictions — after the EMA said the benefits of the vaccine outweighed the risks of not inoculating people against COVID-19. At the time, the EMA recommended the vaccine's leaflet be updated to tell people about the rare clots.
Any further doubts about the AstraZeneca vaccine would be a setback for the shot, which is critical to Europe’s immunization campaign and a linchpin in the global strategy to get vaccines to poorer countries. The AstraZeneca vaccine is cheaper and easier to use than rival vaccines from Pfizer and Moderna and has been approved for use in over 50 countries and groups, including by the 27-nation EU and the World Health Organization. U.S. authorities are still in the process of evaluating the vaccine.
How AstraZeneca's vaccine got mired in politics and mistrust to become Europe's least favorite shot
A succession of communication blunders about the vaccine has led some Europeans to see it as second rate.Merkel's interview with the Frankfurter Allgemeine Zeitung came as governments across Europe realized that mistrust among its people for this particular shot imperiled the continent's entire vaccination drive.
Cavaleri said while EMA was prepared to declare a link, further study was still needed to understand why and how the phenomenon occurs.
“Certainly the information about the product will be updated, affirming that these adverse events are linked to the vaccine. It will be declared in a very clear way,” he was quoted as saying.
U.S. Bet Big on Covid Vaccine Manufacturer Even as Problems Mounted
San Diego State’s Klara Thormalm has been named the Mountain West Swimmer of the Year as voted on by the league’s coaches. Wyoming’s Melissa Mirafuentes was selected as the MW Diver of Year.
He said the rare blood clots, including some in the brain, coupled with a low level of blood platelets that may make people at risk of serious bleeding, “seem to be the key event to study further.” Cavaleri promised more details soon, adding: "In the coming hours, we will say that the link is there, how this happens we still haven’t figured out.”
Blood clots 'very rare' side effect of AstraZeneca vaccine, European regulator says
Because of a small number of blood clots in younger people reported in the U.K., people under 30 will be offered the Pfizer-BioNTech or Moderna vaccines.Emer Cooke, the executive director of the European Medicines Agency, said that the "benefits of the AstraZeneca overall outweigh the risks of side effects.
Cavaleri said the biological mechanism for how the vaccine might be causing the rare clots was still unknown and if it was linked to how the shot is made, other vaccines with similar technologies might also need to be evaluated.
Cavaleri was asked how he could arrive at such a causal conclusion given the relatively few cases of adverse events.
“Among those vaccinated there is a number of cerebral thromboses with a low level of platelets among young people that is higher than what we would have expected. This we have to say,” he was quoted as saying.
But he stressed the risk-benefit analysis remained positive for the AstraZeneca jab, even for young women who appear to be more affected by the clots.
“Let’s not forget that young women also end up in intensive care with COVID. So we need to do very meticulous work to understand if the risk-benefit analysis remains for all ages,” he was quoted as saying.
How AstraZeneca's latest vaccine troubles could slow the global recovery
AstraZeneca's vaccine is key to ending the global economic slump caused by the coronavirus. But a series of missteps by the drugmaker and new concerns over blood clots risk undermining public confidence in the shot and delaying the recovery. © Noah Seelam/AFP/Getty Images A medical worker prepares to innoculate a woman with a dose of AstraZeneca's vaccine in Hyderabad on Apr. 5. European drug regulators confirmed a link between the Oxford-AstraZeneca Covid-19 shot and rare blood clots on Wednesday, but stopped short of recommending its use be limited.
He said the EMA was in a difficult situation, given the different virus outbreaks in each of the EU's 27 nations.
“Certainly, many people would like EMA to resolve the question for everyone, but it’s not that easy,” he said. “In Italy there are still around 500 people dying a day, in Norway nearly no one. These factors justify a different approach.”
He ruled out a preventive therapy to address the rare blood clots, saying there is still too much unknown about the phenomenon.
Even after the March 19 restart, the Dutch and German governments suspended the jabs for people under 60 and some individual Europeans have been shying away from the shot.
The president of Romania’s national vaccination committee, Valeriu Gheorghita, said Tuesday that since March, 207,000 people in Romania had canceled their AstraZeneca vaccine appointments and another 92,000 simply didn’t show up.
“It is a high percentage, a third of people scheduled who did not show up,” Gheorghita told reporters.
British Prime Minister Boris Johnson declined to be drawn directly into the latest warnings about the vaccine, which was developed at Oxford University, but urged people to look at the advice from Britain’s independent Medicines and Healthcare Regulatory Agency.
“Their advice to people is to keep going out there, get your jab, get your second jab,” he said during a visit Tuesday to an AstraZeneca facility in Macclesfield, in northwest England.
Last week, the MHRA said seven people had died in the U.K. due to blood clots after getting the AstraZeneca jab. It said it wasn’t clear if the shots are causing the clot and that it was undertaking a “rigorous review” into the reports. The agency said it had identified 30 blood clot cases out of 18.1 million AstraZeneca doses given by March 24.
Johnson said the rapid rollout of vaccines in the U.K. has helped turn around the situation this year and given Britain the opportunity to roll back lockdown restrictions just as many other countries in Europe are putting them back up amid another surge of the virus.
Follow AP’s pandemic coverage atand
A key component of J&J vaccine could explain link to extremely rare blood clots .
One person has died and another is in critical condition after getting the Johnson & Johnson vaccine. But is the shot to blame?The technology used in the drugmaker’s vaccine, called an adenovirus, is used to prompt an immune response against the coronavirus. But some experts say that it could instead — in rare cases — prompt an immune response against certain components in the blood that cause clotting.